On August 4, 2022, the Company accepted and passed the drug manufacturing certificate inspection, defect rectification review and follow-up inspection on Recombinant Staphylococcus Aureus Vaccine (RSAV) by the inspection team organized by Sichuan Center for Food and Drug Evaluation, Inspection & Monitoring.

The inspection is detailed in the following table. Besides, no penalties were made against the Company's products due to quality since their launch.